Resolution Therapeutics Secures $65 Million in Funding to Revolutionize Inflammatory Organ Disease Treatment with Macrophage Cell Therapy

Resolution Therapeutics is thrilled to announce the successful completion of a $65 million funding round, marking a significant milestone in our mission to revolutionize treatment options for chronic liver disease. Founded as a result of a fruitful collaboration between Edinburgh's Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited, we are at the forefront of biotechnology innovation. Headquartered within the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, we are committed to harnessing the power of macrophage cell therapy to address one of the most pressing health challenges of our time. Chronic liver disease is the only chronic condition on the rise in Western countries, impacting millions worldwide. Currently, treatment options are severely limited to supportive care, and for those at the end-stage of the disease, liver transplantation remains the only viable option despite its complications and donor shortages. Our cutting-edge macrophage cell therapy aims to intervene earlier, targeting patients at risk of liver decompensation and potentially obviating the need for a transplant. This substantial investment will allow Resolution Therapeutics to accelerate clinical trials, advance our product development, and expand our team of experts dedicated to this urgent health crisis. We are grateful for the support of our investors, and we look forward to making a profound impact on the lives of those suffering from chronic liver disease, ultimately improving health outcomes and bringing hope to patients and families around the globe.